1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,007 | 0,008 | 12:40 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:30 | Aptamer Group: Partnership cash helping to fund development | 1 | The Armchair Trader | ||
| 09:10 | Pharma-Verträge treiben Umsatz der Aptamer Group um 27 % | 1 | Investing.com Deutsch | ||
| 08:54 | Aptamer Group reports 27% revenue increase in first half | 1 | Investing.com | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 08:10 | Aptamer Group PLC - Interim Results and Notice of Investor Webinar | 3 | RNS | ||
| 08:00 | Aptamer Group PLC - Proposed Placing, Subscription and Retail Offer | 1 | RNS | ||
| 18.03. | Aptamer Group Introduces Targeted Radiopharmaceutical Program | 1 | Contract Pharma | ||
| 18.03. | Aptamer launches targets radiopharma development programme | 2 | Sharecast | ||
| 18.03. | Aptamer Group PLC - Launch of targeted radiopharmaceutical programme | - | RNS | ||
| 17.02. | Aptamer Group meldet wichtigen Meilenstein bei Projekt zur Pathogenerkennung | 2 | Investing.com Deutsch | ||
| 17.02. | Aptamer Group achieves technical milestone in pathogen detection project | 1 | Investing.com | ||
| 17.02. | Aptamer Group PLC - Technical Feasibility for Pathogen Detector | 1 | RNS | ||
| 11.02. | Aptamer Group PLC - Optimer Technology in Launched Library Prep Kit | - | RNS | ||
| 29.01. | Aptamer Group PLC - Contract wins and first cash licensing receipts | 1 | RNS | ||
| 07.01. | Aptamer Group PLC - Trading update - Media comment and speculation | - | RNS | ||
| 07.01. | Aptamer shares slide despite revenue improvement | 1 | Sharecast | ||
| 07.01. | TRADING UPDATES: EnSilica hails "solid" half-year; Aptamer revenue up | 3 | Alliance News | ||
| 07.01. | Aptamer Group PLC - Half Year Trading Update | 1 | RNS | ||
| 23.12.25 | IN BRIEF: Aptamer signs Optimer contract with US biotech Alphazyme | 1 | Alliance News | ||
| 23.12.25 | Aptamer Group inks Optimer licensing agreement with Alphazyme | 2 | Sharecast | ||
| 23.12.25 | Aptamer Group PLC - Aptamer signs licensing agreement with Alphazyme | - | RNS |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS | 21,380 | +0,09 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,330 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,640 | 0,00 % | Why Edgewise Therapeutics Stock Topped the Market on Tuesday | ||
| KINIKSA PHARMACEUTICALS | 44,940 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,570 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,66 | 0,00 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| APOGEE THERAPEUTICS | 72,98 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 34,945 | +1,39 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,060 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 12,330 | 0,00 % | Stifel reiterates Buy on Contineum stock, keeps $29 price target | ||
| BIONTECH | 76,05 | +1,13 % | Biotech-Werte im Check: Warum Emyria, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| TANGO THERAPEUTICS | 19,480 | 0,00 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| ERASCA | 14,645 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| EVOTEC | 4,379 | +6,31 % | Welche Aktie jetzt kaufen? Evotec, Nel und Lahontan Gold. | Was ist denn da bei Nel los? Innerhalb weniger Tage hat die einstige Wasserstoffhoffnung über 20 % an Wert gewonnen. Der kurzfristige Abwärtstrend wurde verlassen. Doch Analysten sehen keine Trendwende.... ► Artikel lesen | |
| LENZ THERAPEUTICS | 9,010 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Launched VIZZ- (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for... ► Artikel lesen |
Das Unternehmen APTAMER GROUP PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,015 (+263,64 %) liegt der Kurs bei 0,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAMER GROUP PLC finden Sie auf Wallstreet Online.